News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Credit Default Swap News, Articles and Videos with Contenting
A credit default swap (CDS) is a financial derivative contract between two parties. The buyer of the CDS makes a series of payments to the seller, and in exchange, the seller agrees to pay the buyer in the event of a loan default. Credit default swaps are typically used to protect against the risk of a borrower defaulting on their loan. By buying a CDS, the buyer is essentially taking out an insurance policy on the borrower's loan. There are many different types of CDS contracts, and they can be used to hedge against a variety of risks. This news and analysis section covers the latest news, trends and developments in the credit default swap market.
Best Interest Rates Survey: Savings Accounts, Treasuries, CDs, Money Markets, ETFs – June 2025 — My Money Blog
Here’s my monthly survey of the best interest rates on cash as of June 2025, roughly sorted from shortest to longest maturities. Banks and brokerages love taking advantage of our idle cash, a…
CDSC Digitizes 16 Billion Safaricom Shares in Landmark Shift from Physical to Electronic Format. - Envestreet Financial
The Central Depository and Settlement Corporation (CDSC) has successfully completed the immobilization of 16 billion Safaricom PLC shares, a development heralded as a transformative leap for Kenya’s capital markets and financial infrastructure. The move shifts Safaricom’s shares from physical certificates into electronic format, held securely within the Central Depository System (CDS), enhancing transparency, efficiency, and […]
Ebenbuild Secures Euro 2.3 Million EIC Grant to Scale Digital Twin Platform for Respiratory Health - ForexTV
Funding supports market launch of platform for clinical and commercial applicationsCompany targets Euro 15 billion in silico trials market and ICU decision support Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care. Twinhale is the first scalable simulation tool that enables physiologically accurate, patient-specific predictions of drug deposition in the lungs. Built on Ebenbuild’s proprietary technology platform, it offers pharmaceutical and medtech companies a cost-efficient technology to digitally simulate pulmonary drug delivery – potentially reducing trial failure rates and costs as well as time-to-market. Ebenbuild has already applied its Twinhale software in pilot studies with PARI Pharma and Pieris Pharmaceuticals. In a validation study, Twinhale predicted local drug deposition with unprecedented accuracy, outperforming existing models and enabling design decisions that are typically inaccessible through in vivo or in vitro testing. Backed by HTGF, Bayern Kapital and angel investors, Ebenbuild operates in a rapidly growing Euro >5 billion in silico trials market and is positioning itself to enter the clinical decision support systems (CDSS) and personalized medicine markets, collectively estimated at over €300 billion by 2030. The EIC grant provides non-dilutive capital and validation from one of the most competitive tech funding programs in Europe. “Our vision is to become the leading health intelligence platform for respiratory diseases,” said Dr. Kei Müller, CEO and Co-founder of the Company. “Twinhale is just the beginning. The very same core platform will power future regulated products for mechanical ventilation optimization and chronic respiratory disease management.” Dr. Maximilian Grill, Head of In Silico Trials at Ebenbuild, added: “With Twinhale, we are not only reducing attrition rates in respiratory drug development – we are also generating first-of-its-kind datasets that can drive regulatory acceptance and unlock companion diagnostic strategies in the future.” The Company’s long-term roadmap spans from preclinical simulations to clinical-grade decision support systems. As a follow-up product, Ebenbuild develops a software for optimizing mechanical ventilation in patients with lung complications – a Euro 10 billion market segment with strong clinical demand rapid feedback cycles, and clear economic benefits. ### About EbenbuildEbenbuild is a digital health tech pioneer developing precise computer models of lungs based on patient-specific data, i.e. digital twins of the lungs. Its digital toolset is based on physics-based simulation, A.I., and data science and is designed to support decision makers in the life sciences and healthcare industries. Ebenbuild’s platform technology deepens the understanding of respiratory diseases and individual pathophysiology. It enables products ranging from personalized decision support to improve patient outcomes in severe respiratory diseases to in silico trials to accelerate and de-risk the development of inhaled drugs.www.ebenbuild.com About EIC Accelerator The EIC Accelerator offers start-ups and SMEs grants of up to €2.5 million combined with equity investments through the EIC Fund ranging from €0.5 to €15 million (up to €10 million as of 2025). In addition to financial backing, all projects benefit from Business Acceleration Services, which provide access to leading expertise, corporate partners, investors, and ecosystem actors. Company ContactEbenbuildDr. Jonas Biehlerbiehler@ebenbuild.com Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64 / +49 30 23 63 27 68
First Bancshares, Inc. Announces Operating Results for Quarter Ended June 30, 2025 - ForexTV
MOUNTAIN GROVE, Mo., July 11, 2025 (GLOBE NEWSWIRE) -- First Bancshares, Inc. (OTCQX: FBSI) (“Company”), the holding company for Stockmens Bank (“Bank”), today announced its unaudited financial results for the quarter ended June 30, 2025. For the second quarter of 2025, the Company reported after-tax net income of $1,824,000 or $0.75 per share-diluted compared to $1,630,000 or $0.67 per share-diluted for the same period in 2024. Net income for the second quarter of 2025 represents an after-tax return on average assets of 1.36% and an after-tax return on equity of 11.82%. These earnings ratios repeated their recent trend of outperformance despite an atypical $7.5 million increase in asset size due to an arbitrage play and strategic stockpiling of capital reserves. Since June 30, 2024, the Company experienced growth in all major balance sheet categories aside from investment securities with consolidated total assets increasing $27.3 million to $544.1 million, cash & cash equivalents increasing $13.0 million to $55.8 million, and net loans receivable increasing $15.9 million to $445.3 million. Total deposits increased $13.4 million to $468.3 million, and stockholders’ equity increased $6.3 million to $62.3 million. Through the second quarter of 2025, the Company has made significant efforts to fortify its balance sheet. Liquidity remains robust with excess cash being deployed into high-quality loan assets, earning asset yields rose, costs of funds has been kept in check, asset quality improved from already impressive levels, and capital ratios developed to a level that affords the Company the flexibility to pursue growth opportunities as they arise. The Bank meets all regulatory requirements for “well-capitalized” status. About the Company First Bancshares, Inc. is the holding company for Stockmens Bank, a FDIC-insured commercial bank chartered by the State of Colorado that conducts business from its home office in Colorado Springs, Colorado, and eight full-service Missouri offices in Mountain Grove, Marshfield, Ava, Kissee Mills, Gainesville, Crane, Hartville and Springfield, and full-service offices in Bartley, Nebraska and Akron, Colorado. Cautionary Note Regarding Forward-Looking Statements The Company and its wholly owned subsidiary, Stockmens Bank, may from time to time make written or oral “forward-looking statements” in its reports to shareholders, and in other communications by the Company, which are made in good faith by the Company pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements with respect to the Company’s beliefs, expectations, estimates and intentions that are subject to significant risks and uncertainties, and are subject to change based on various factors, some of which are beyond the Company’s control. Such statements address the following subjects: future operating results; customer growth and retention; loan and other product demand; earnings growth and expectations; new products and services; credit quality and adequacy of reserves; results of examinations by our bank regulators, technology, and our employees. The following factors, among others, could cause the Company’s financial performance to differ materially from the expectations, estimates and intentions expressed in such forward-looking statements: the strength of the United States economy in general and the strength of the local economies in which the Company conducts operations; the effects of, and changes in, trade, monetary, and fiscal policies and laws, including interest rate policies of the Federal Reserve Board; inflation, interest rate, market, and monetary fluctuations; the timely development and acceptance of new products and services of the Company and the perceived overall value of these products and services by users; the impact of changes in financial services’ laws and regulations; technological changes; acquisitions; changes in consumer spending and savings habits; and the success of the Company at managing and collecting assets of borrowers in default and managing the risks of the foregoing. The foregoing list of factors is not exclusive. The Company does not undertake, and expressly disclaims any intent or obligation, to update any forward-looking statement, whether written or oral, that may be made from time to time by or on behalf of the Company. Contact: Robert M. Alexander, Chairman and CEO - (719) 955-2800 First Bancshares, Inc. and Subsidiaries Financial Highlights (unaudited) (In thousands, except per share amounts) Quarter Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating Data: Total interest income $8,407 $8,013 $16,371 $16,154 Total interest expense 2,411 2,689 4,721 5,486 Net interest income 5,996 5,324 11,650 10,668 Provision for credit losses 61 141 239 343 Net interest income after provision for credit losses 5,935 5,183 11,411 10,325 Gain (loss) on sale of investments - - - - Non-interest income 474 410 835 786 Non-interest expense 4,014 3,434 7,597 6,757 Income before taxes 2,395 2,159 4,649 4,354 Income tax expense 571 529 1,133 1,071 Net income $1,824 $1,630 $3,516 $3,283 Earnings per share $0.75 $0.67 $1.46 $1.35 At At At June 30, December 31, June 30, Financial Condition Data: 2025 2024 2024 Cash and cash equivalents $55,758 $68,570 $42,769 (excludes CDs) Investment securities 13,421 13,066 12,966 (includes CDs) Loans receivable, net 445,372 423,657 429,444 Goodwill and intangibles 1,443 1,515 1,586 Total assets 544,072 537,885 516,784 Deposits 468,345 472,596 454,992 Repurchase agreements 1,102 1,084 1,601 Borrowings 7,500 - - Stockholders' equity 62,336 59,562 56,037 Book value per share $25.68 $24.53 $23.08